ARCOMA Share Price | Arcoma AB Stock Analysis & Recommendation

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Compare Arcoma AB with Similar Stocks

Ziccum AB Acarix AB AroCell AB

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

The company has declared negative results in Dec'2024 after 6 consecutive positive quarters

NET PROFIT(9M) At SEK 2.99 MM has Grown at -52.35%
OPERATING CASH FLOW(Y) Lowest at SEK 18.72 MM
INTEREST COVERAGE RATIO(Q) Lowest at 13,970.37

With ROE of 8.26%, it has a fair valuation with a 2.14 Price to Book Value

Underperformed the market in the last 1 year

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

SEK 114 Million (Micro Cap)

P/E

26.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.47

Return on Equity

6.73%

Price to Book

1.53

Revenue and Profits:

Net Sales:

35 Million

(Quarterly Results - Dec 2025)

Net Profit:

1 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

11.2%

6 Months

-9.35%

1 Year

-16.1%

2 Years

-29.92%

3 Years

-8.75%

4 Years

-14.02%

5 Years

-60.85%

Arcoma AB for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

2.18%

EBIT Growth (5y)

18.40%

EBIT to Interest (avg)

3.04

Debt to EBITDA (avg)

Net Debt is too low

Net Debt to Equity (avg)

-0.13

Sales to Capital Employed (avg)

2.60

Tax Ratio

26.39%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

11.35%

ROE (avg)

6.76%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.14

EV to EBIT

10.70

EV to EBITDA

6.32

EV to Capital Employed

2.51

EV to Sales

0.87

PEG Ratio

Dividend Yield

ROCE (Latest)

23.44%

ROE (Latest)

8.26%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bullish

Bearish

Dow Theory

Mildly Bullish

OBV

Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 16.05% vs -4.78% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -12.50% vs 0.00% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "34.70",
          "val2": "29.90",
          "chgp": "16.05%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "3.80",
          "val2": "4.10",
          "chgp": "-7.32%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1.40",
          "val2": "1.60",
          "chgp": "-12.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "60.20%",
          "val2": "74.50%",
          "chgp": "-1.43%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is -16.58% vs -3.80% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -55.36% vs 330.77% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "130.80",
          "val2": "156.80",
          "chgp": "-16.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "16.00",
          "val2": "16.50",
          "chgp": "-3.03%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.30",
          "chgp": "-66.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "5.00",
          "val2": "11.20",
          "chgp": "-55.36%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "66.40%",
          "val2": "99.10%",
          "chgp": "-3.27%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

34.70

29.90

16.05%

Operating Profit (PBDIT) excl Other Income

3.80

4.10

-7.32%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

1.40

1.60

-12.50%

Operating Profit Margin (Excl OI)

60.20%

74.50%

-1.43%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 16.05% vs -4.78% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is -12.50% vs 0.00% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

130.80

156.80

-16.58%

Operating Profit (PBDIT) excl Other Income

16.00

16.50

-3.03%

Interest

0.10

0.30

-66.67%

Exceptional Items

0.00

Consolidate Net Profit

5.00

11.20

-55.36%

Operating Profit Margin (Excl OI)

66.40%

99.10%

-3.27%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is -16.58% vs -3.80% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -55.36% vs 330.77% in Dec 2024

All Annual Results

Company CV

About Arcoma AB

Arcoma AB

Pharmaceuticals & Biotechnology

Arcoma AB is a Sweden-based medical technology company. It develops, produces and markets digital radiographic systems. Its products offer digital imaging technology combined with advanced mobile positioning system. The Company's product portfolio comprises: complete radiographic systems available as ceiling suspensions and floor mounted systems, as well as detectors; radiographic system components, such as overhead tube crane, cube, tilting wall stand and radiographic tables; and mobile imaging tables in two series, namely Precision and Elite. Its products are designed for hospitals, clinics, imaging centers and private practices, and available through three market channels: its own brand IMIX, private label distributors and original equipment manufacturers (OEM).

Company Coordinates

Company Details

Annavagen 1 , VAXJO None : 352 46

Tel: 46 470 706900

http://arcoma.se/

Registrar Details